<DOC>
	<DOC>NCT02301988</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, multicenter, pre-operative Phase II study designed to estimate the efficacy of ipatasertib combined with paclitaxel chemotherapy versus placebo combined with paclitaxel chemotherapy in women with Stage Ia - IIIa triple-negative breast adenocarcinoma. The anticipated time on study treatment is 12 weeks. The target sample size is 130.</brief_summary>
	<brief_title>A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Premenopausal or postmenopausal women, age &gt;/=18 years Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Histologically documented, Stage Ia to operable Stage IIIa, triplenegative carcinoma of the breast with primary tumor &gt;/=1.5 cm in largest diameter (cT13) by magnetic resonance imaging (MRI) Adequate hematologic and organ function within 14 days before the first study treatment Availability of tumor tissue from formalinfixed, paraffinembedded (FFPE) core biopsy of breast primary tumor For female patients of childbearing potential, agreement to use highly effective form(s) of contraception for the duration of the study and for at least 6 months after last dose of study treatment Known HER2positive, ERpositive, or PgRpositive breast cancer Any prior treatment for the current primary invasive breast cancer Patients with cT4 or cN3 stage breast tumors Metastatic (Stage IV) breast cancer Bilateral invasive breast cancer Multicentric breast cancer Any disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>